At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 12, 2026 at 08:00 ET
Theriva Biologics reported Q3 2026 net loss of $1.47M ($0.03 per share), narrower than the $4.36M loss a year ago, driven by a 76% drop in R&D spending after completing the VIRAGE Phase 2b trial. Cash of $8.5M provides runway only into Q1 2027, and the company completed the sale of its SYN-004 microbiome assets for $350K upfront plus milestones. The VIRAGE2 trial is expected to complete enrollment in Q4 2026 with initial data by Q3 2027.
- Q3 2026 net loss $1.47M ($0.03 per share) vs $4.36M ($0.45) in Q3 2025
- Cash and equivalents $8.5M as of Sep 30, 2026, down from $13.1M at Dec 31, 2025
- Cash runway into Q1 2027
- VIRAGE2 Phase 2a enrollment expected to complete Q4 2026, initial data by Q3 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access